Pocket Clinic

Pocket Clinic is developing a smart injector aiming to provide advanced and personalized therapy for diabetics. Our team aims to rethink the entire control, and drug delivery procedures by introducing a minimally invasive smartphone-controlled compact medical device. Our solution uses an online machine learning platform capable of analyzing glucose levels and optimizing the insulin-dosing algorithm while delivering updates to caregivers and family members.

-Q 2018 finished the first prototype
-Q 2019 finished the mobile application prototype
-Q2 2019 received the first investment
current status: finishing the manufacturing design, finishing the mobile application with full services, ready to apply for the regulatory process, starting the negotiation with agencies to register the product in ANVISA

male and female insulin-dependent diabetics that can handle the gadget like smartphone, smartwatch, and the age between 6-80. The market size of the tubeless insulin pump estimated to reach 2.4 billion USD by 2025.

An estimated 463 million adults aged 20–79 years are currently living with diabetes. This represents 9.3% of the world’s population in this age group. The total number is predicted to rise to 578 million (10.2%) by 2030 and to 700 million (10.9%) by 2045. Life of 10 % of them depends on the drug called insulin Although this is a lifesaver and keeps them alive it is not an easy drug to administer. In this modern time still, most diabetics use old fashioned treatment which is a syringe and it causes overdose or underdose due to inaccurate calculation that they make. Imagine that they are dealing with unfixed dose drug 24 x 7 for a lifetime. An estimated 1.1 million children and adolescents (aged under 20 years) have type 1 diabetes. The number of newly diagnosed cases TD1 (0-19 years) each year 128,900 add to this number. It is estimated that 79.4% of diabetics live in low- and middle-income countries.

Pocket Clinic is developing a smart injector aiming to provide advanced and personalized therapy for diabetics. Our team aims to rethink the entire control, and drug delivery procedures by introducing a minimally invasive smartphone-controlled compact medical device. Our solution uses an online machine learning platform capable of analyzing glucose levels and optimizing the insulin-dosing algorithm while delivering updates to caregivers and family members.

-Medtronics
-Roche
-Cellnovo
-Bigfoot medical
-Insulet
-DIY loop solution that diabetics develop it by themselves and it doesn't have regulatory approval.

Drug delivery system, Fully controlled by smartphone or smartwatch
The low-cost solution that is suitable for all middle or law income classes
Miniaturize the size of the drug delivery system in the market
Pain-Free, using microneedle to inject the drug.
Open protocols, meaning that it has the ability to work with any sensor or any algorithm available in the market.

5 years contract for the main pod (rechargeable pod) for about $1000 -$ 1500 annually
monthly subscription for 10 units of the cartridge ( disable part) for about $600- $650 monthly
besides that in the mobile application, we are providing services like psychology, nutrition, activity for patients that is a subscription model.

Our estimation is to reach 20.000 patients in the first two years of operation, in order to reach that number we are planning to leverage from social networks whilst offering them an innovative product that solves problems that the competitors don't. In order to do this, we plan to introduce an innovative business model, never used before in the medical devices market for diabetics.we intend to market our solution via a monthly subscription service thereby eliminating the required large upfront investment, On the one hand, this will enable diabetics from lower economic classes to access our solution and on the other, the National Health Services will ensure costs are only incurred in line with the usage of the healthcare solution.

1- Renting a location for establishing a factory
2- Buying the machinery and production line
3- Applying for the regulatory process (ANVISA, FDA, CE)
4- hiring and expanding the team ( App developer, Electronic engineer, Mechanical engineer, MD)
5- Purchasing the materials and components for first batch

SAFE contract

-Regulatory risk, causes both technical and commercial risk as there is a lack of clear process duration.
-Competitors, pivoting their solution to a similar integrated concept
-The entrance of a more effective or innovative, cause us to rethink our insulin delivery systems

Brinc - International IoT acceleration

-Innovation Latam Award - Health Tech sector
honor dateOct 2019 honor issued innovation Latam
-Global Entrepreneur Programme
honor dateMar 2018 honor issue UK Department for International Trade
-Third place in the Leaders in Innovation Fellowship final Pitch session
honor dateOct 2017 honor issuerRoyal Academy of Engineering

PCT patent pending for smart injector